Vascular Access Site Complications After Percutaneous Coronary Intervention With Abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Trial

Thrombolytic therapy or intense anticoagulation during percutaneous transluminal coronary revascularization (PTCR) increases the risk of vascular access site complications. This study evaluated the association of abciximab, a glycoprotein IIb/IIIa receptor blocker, with vascular access site complica...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1998, Vol.81 (1), p.36-40
Main Authors: Blankenship, James C., Hellkamp, Anne S., Aguirre, Frank V., Demko, S.Lee, Topol, Eric J., Califf, Robert M.
Format: Article
Language:English
Subjects:
Abciximab
Angioplasty
Angioplasty, Balloon, Coronary - methods
Antibodies, Monoclonal - adverse effects
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Catheters, Indwelling - adverse effects
Clinical trials
Drugs
Female
Hematocrit
Hemorrhage
Hemorrhage - blood
Hemorrhage - etiology
Humans
Immunoglobulin Fab Fragments - adverse effects
Incidence
Infusions, Intravenous
Injections, Intravenous
Length of Stay
Logistic Models
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - adverse effects
Prospective Studies
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombolytic therapy or intense anticoagulation during percutaneous transluminal coronary revascularization (PTCR) increases the risk of vascular access site complications. This study evaluated the association of abciximab, a glycoprotein IIb/IIIa receptor blocker, with vascular access site complications after PTCR. Of 2,058 patients who underwent PTCR in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial, major vascular access site bleeding (a drop in hematocrit >15%), minor vascular access site bleeding (>10% drop), or surgical repair of the access site occurred in 5%, 12%, and 1.4% of all patients, respectively. Minor and/or major bleeding or surgery occurred in 21.8% of abciximab patients, compared with 9.1% of placebo patients (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(97)00796-0